Pfizer today announced the results of the clinical trial of its coronavirus vaccines for children ages 5 to 11. It is still awaiting approval from regulatory agencies, such as the FDA or the European Medicines Agency (EMA). However, they can already anticipate that the results have been very similar to those obtained with adults.
Specifically, as described in a statement, it is concluded that it is a vaccine safe, well tolerated and with a robust response from neutralizing antibodies against SARS-CoV-2.
But what else do we know about her? Are the results comparable to what we have seen in adults all this time? Fortunately, the results indicate that there is nothing to fear.
An open door to coronavirus vaccines for children
Although several companies had announced that they would begin testing their coronavirus vaccines in children, Pfizer was the first to publish results.
The dose is lower than in adults, but otherwise it is the same vaccine
It has done so after the completion of a clinical trial in which they have participated 2,268 children from 5 to 11 years old. Two other clinical trials are also under way, one with babies 6 months to 2 years and another with children 2 to 5 years. However, the results of these two are not expected to arrive until the end of the year.
At the moment, we know that the only difference from Pfizer’s coronavirus vaccines for adults has been the dose. While people 12 years of age and older have received two 30 microgram doses, the children have been administered two doses of 10 micrograms. Regarding the distance between doses, it has been the same: 21 days.
The results obtained by measuring the neutralizing antibodies against SARS-CoV-2 they have been equivalent to those of adults aged 16 to 25 years. And the same goes for side effects.
No change in Pfizer vaccine
These Pfizer coronavirus vaccines for children remain the same as for adults. Therefore, the technology of the Messenger RNA, which encourages our own cells to manufacture a SARS-CoV-2 protein, in order to trick the immune system and lead it to generate antibodies against the pathogen.
We already know that group immunity, as described at the beginning, is impossible to achieve, even more so after the appearance of the latest variants. Therefore, it is important to vaccinate largest possible percentage of population. And that is something that also includes children. Especially now that the course has started, it is a vulnerable population for not being vaccinated. For this reason, once the FDA, the EMA and the rest of the agencies give the go-ahead, it is foreseeable that governments will soon include the little ones in the household in vaccination campaigns. But for that we will still have to wait a bit. We will remain attentive to the news.